tiprankstipranks
pc:sparr

Sparrow Pharmaceuticals

Sparrow Pharmaceuticals is a targeted cardiometabolic therapeutics company focused on improving outcomes for patients with type 2 diabetes and related metabolic conditions. The company's lead candidate, clofutriben, is an oral HSD-1 inhibitor designed to address elevated cortisol levels, a key factor in treatment resistance and disease progression. Clofutriben aims to complement existing antidiabetic therapies by offering a novel mechanism of action that enhances glycemic control and addresses a spectrum of metabolic dysfunctions.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$95M
Total Amount Raised$95M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$95M
Latest Funding Amount$95M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Sep 24, 2025
Series B
$95.00M

Investors

Investor Name
Funding Round

Related News and Analysis